Prescription drug · NDA
Qulipta (Atogepant) NDC 0074-7094
Atogepant 60 mg/1 · Tablet · Oral · AbbVie Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0074-7094-04 | 00074709404 | 4 TABLET in 1 BOTTLE (0074-7094-04)Marketed from Oct 6, 2021 · Sample package | |
| 0074-7094-30 | 00074709430 | 30 TABLET in 1 BOTTLE (0074-7094-30)Marketed from Sep 30, 2021 | |
| 0074-7094-70 | 00074709470 | 4 TABLET in 1 BOTTLE (0074-7094-70)Marketed from Dec 17, 2025 · Sample package |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Qulipta
- Generic name (nonproprietary)
- atogepant
- Active ingredients
- Atogepant — 60 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- AbbVie Inc.NDC labeler code 0074
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 215206
- Marketing start
- Listing expires
- Other FDA classes
- Calcitonin Gene-related Peptide Receptor Antagonists (Mechanism)
- Identifiers
- Product ID 0074-7094_392c0320-ca25-423a-9bc1-d06f6badab07SPL ID 392c0320-ca25-423a-9bc1-d06f6badab07SPL set ID 8c8ab8f4-32bd-497a-befa-70c8a51d8d52RxCUI 2571836, 2571842, 2571844, 2571846, 2571848, 2571850UNII 7CRV8RR151UPC 0300747096305, 0300747094301
- Pharmacologic class
- Calcitonin Gene-related Peptide Receptor Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400074709404followed by a unit qualifier and the quantityPackage 00074-7094-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
QULIPTA is indicated for the preventive treatment of migraine in adults. QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 0074-7094
- What is NDC 0074-7094?
- 0074-7094 is the product NDC for Qulipta (atogepant), Atogepant 60 mg/1 tablet, listed with the FDA by AbbVie Inc.. It has 3 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Qulipta (Atogepant).
- What is the active ingredient?
- Atogepant.
- Who is the labeler?
- AbbVie Inc., NDC labeler code 0074. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Qulipta?
- 2 other product NDCs are listed under this name. See all Qulipta NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Qulipta products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Quliptaatogepant | Atogepant 30 mg/1 | TabletOral | AbbVie Inc. | 0074-7096 | 00074-7096-0400074-7096-3000074-7096-70 |
| Quliptaatogepant | Atogepant 10 mg/1 | TabletOral | AbbVie Inc. | 0074-7095 | 00074-7095-30 |
Other NDCs under NDA 215206
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Quliptaatogepant | Atogepant 30 mg/1 | TabletOral | AbbVie Inc. | 0074-7096 |
| Quliptaatogepant | Atogepant 10 mg/1 | TabletOral | AbbVie Inc. | 0074-7095 |